Coverage
-
October 03, 2014
The Federal Circuit will hear arguments Monday in a case that may clarify whether the U.S. Supreme Court's decision that Myriad Genetics Inc. cannot patent human genes invalidates other inventions involving natural products, as Myriad appeals the denial of an injunction in a case over its cancer-testing patents.
2 other articles on this case.
View all »